The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid

Cancer 2007 Mar;109(6):1090-6

View abstract

Authors

Oh W, Proctor K, Nakabayashi M, Evan C, Tormey L, Daskivich T, Antras L, Smith M, Neary M, Duh M